CAR T Cell Therapy Shows Promise in Acute Myeloid Leukemia

News   May 10, 2018 | Original story from Moffitt Cancer Centre

 
CAR T Cell Therapy Shows Promise in Acute Myeloid Leukemia

Relapsed AML patient treated with CYAD-01 CAR-T therapy. CD34 IHC of the core biopsy shows clusters of blasts (~7%) consistent with relapsed disease (Panel A). Prominent dysmegakaryopoiesis was also noted (Panel B). BM biopsy at day +56 following 3 infusions of CYAD-01 showed normal trilineage hematopoiesis with CD34 IHC showing no increase in blasts (Panel C). Patient also with significant improvement of hematopoiesis as transfusion independent with marked increase of hemoglobin and platelet count (Panel D). Credit: doi:10.3324/haematol.2017.186742

 
 
 

RELATED ARTICLES

Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

News

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.

READ MORE

New Chemistry to Make Smart Drugs Smarter

News

A method to activate targeted drugs, or smart drugs, only at the selected site of action, an approach that improves the drug’s therapeutic effect and minimizes side effects, has been developed in a study led by Georgia State University.

READ MORE

Artificial Cellular Compartments Built

News

How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE